HDAC9 and Miyoshi myopathy: HDAC inhibitors have potential therapeutic effects on cancers and can be used in combination with a variety of chemotherapies and immunotherapies, and the synergy between bortezomib and HDAC inhibitors has been reported in MM and other hematological malignancy cells [41–43].